Monte Rosa Therapeutics (NASDAQ:GLUE) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum [Yahoo! Finance]
Monte Rosa Therapeutics announces pricing of $300M stock offering [Seeking Alpha]
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $22.00 to $30.00. They now have an "overweight" rating on the stock.